CollPlant Biotechnologies Ltd

Public Equity (Nasdaq)BiotechPublicRegenerative Medicine

📍 Rehovot, Israel• Founded 2004

StreetZero Signal 54

Be the first to signal interest

About CollPlant Biotechnologies Ltd

CollPlant Biotechnologies Ltd is an Israeli regenerative medicine company developing plant-derived human collagen for tissue repair and 3D bioprinting applications. Its rhCollagen technology is used in medical aesthetics and orthopedics. The company is listed on the Nasdaq under ticker CLGN.

LATEST FUNDINGRule 144

$59K

Announced 2026-10-27

🔒

Unlock the full deal profile

Create a free account to see investors, key highlights, news, company details and the AI analysis for CollPlant Biotechnologies Ltd.

Create free account Sign in

Free plan includes 3 full deal profiles every month.

EMPLOYEES—

FOUNDED2004

HQRehovot, Israel

Industry

Public Equity (Nasdaq)

Investors

Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.

Key highlights

Publicly traded on Nasdaq (CLGN)
Develops plant-based collagen technology
Focuses on 3D bioprinting and aesthetics

Ask StreetZero about CollPlant Biotechnologies Ltd

Put our AI to work on this deal.

What is CollPlant Biotechnologies Ltd's value proposition?Who are CollPlant Biotechnologies Ltd's competitors?Why does this raise matter?Summarize CollPlant Biotechnologies Ltd for an investor.

Similar companies

Other Public Equity (Nasdaq) deals, ranked by Signal.

Paylocity Holding Corporation

$66.0M

BENTLEY SYSTEMS INC

$67.5M

Crowdstrike Holdings, Inc.

$141.0M

Palo Alto Networks Inc

$201.4M

Source document & SEC filing

The source SEC filing and the cached document are available to members only. Sign in to view and download them.